

REMARKS

Applicants elect antisense nucleic acids complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3). The election is made without traverse. Applicants have amended the claims to reflect this election. No new matter has been added.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

August 23 2002

Kristina Bieker-Brady

Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110-2106
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

Version of Claims Showing Changes Made Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

5. (Amended) A method of inducing apoptosis in a cell[, said cell] in a mammal diagnosed as having [with] a proliferative disease, said method comprising administering to said [cell An] mammal an antisense nucleic acid of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity [*in vitro*], wherein said antisense nucleic acid is complementary to a portion of a [mammalian IAP nucleic acid sequence] selected from the group consisting of:] human X-linked IAP (XIAP) (SEQ ID NO:3)[, human IAP-1 (HIAP-1) (SEQ ID NO:5), human IAP-2 (HIAP-2) (SEQ ID NO:7); murine XIAP (SEQ ID NO:9), murine HIAP-1 (SEQ ID NO:11), and murine HIAP-2 (SEQ ID NO:13)].

Claims Pending After Entry of Amendment, Pursuant to 37 C.F.R. § 1.121(c)(3)

5. A method of inducing apoptosis in a cell in a mammal diagnosed as having a proliferative disease, said method comprising administering to said mammal an antisense nucleic acid of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense nucleic acid is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

9. A method of treating a patient diagnosed as having a proliferative disease, said method comprising administering to said patient an antisense nucleic acid of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense nucleic acid is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

10. (New) The method of claim 9, wherein said mammal is a human.

11. (New) The method of claim 9, wherein said proliferative disease is cancer.

12. (New) The method of claim 11, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.

13. (New) The method of claim 5, wherein said mammal is a human.

14. (New) The method of claim 5, wherein said proliferative disease is cancer.

15. (New) The method of claim 14, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.